What's new

Human medicines European public assessment report (EPAR): Fluenz, influenza vaccine (live attenuated, nasal), Date of authorisation: 03/06/2024, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Fluenz, influenza vaccine (live attenuated, nasal), Date of authorisation: 03/06/2024, Revision: 4, Status: Authorised

Apr 7, 2025 - 15:43
 0
Human medicines European public assessment report (EPAR): Fluenz, influenza vaccine (live attenuated, nasal), Date of authorisation: 03/06/2024, Revision: 4, Status: Authorised
Human medicines European public assessment report (EPAR): Fluenz, influenza vaccine (live attenuated, nasal), Date of authorisation: 03/06/2024, Revision: 4, Status: Authorised
Read More

Tags:

Previous Article

CDMO AmplifyBio closes doors amid tough market for early-stage cell and gene the...

Next Article

LS Power eyes 300-MW colocated data center at Virginia power plant

Related Posts

Human medicines European public assessment report (EPAR): Jaypirca, pirtobrutinib, Date of authorisation: 30/10/2023, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 9, 2025  0

EMEA-002762-PIP02-20-M02

EMEA-002762-PIP02-20-M02

Feb 14, 2025  0

Orphan designation: Rilzabrutinib Treatment of autoimmune haemolytic anaemia, 16/01/2025 Positive

Orphan designation: Rilzabrutinib Treatment of autoimmu...

Feb 20, 2025  0